Pretreated EGFRdel19/BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report

Pretreated EGFRdel19/BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report

Oncogene-addicted NSCLC inevitably becomes resistant to targeted therapy by developing acquired resistance through on- or off-target mechanisms, potentially detectable by liquid biopsy. We present the first reported case of a patient with pretreated EGFRdel19/BRAFV600E lung adenocarcinoma and sympto...

Full description

Bibliographic Details
Main Authors: Corrado Orciuolo, MD, Federico Cappuzzo, MD, Lorenza Landi, MD, Blerina Resuli, MD, Silvia Carpano, MD, Antonello Vidiri, MD, Simonetta Buglioni, MS, Chiara Mandoj, MD, Gennaro Ciliberto, MD, Gabriele Minuti, MD
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:JTO Clinical and Research Reports
Subjects:
NSCLC
Case report
Targeted therapy
Osimertinib
Resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323000887

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323000887

Similar Items